Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics.
$3.73+1.91%
报价 2026-11-06
市值
$15.1M
EV
$-19.3M
PE (TTM)
0.2x
预期 PE (FY2026)
–
52 周区间距高点 -66.1%
$3.66$11.00
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| KYNBKyntra Bio, Inc. | $15.1M | +1.9% | +16.2% | 75.8% | 0.2x | – | – | |
| XFORX4 Pharmaceuticals, Inc. | $315.3M | +3.6% | -73.4% | 81.2% | – | – | – | |
| OKUROnKure Therapeutics, Inc. | $116M | +13.5% | -28.6% | 0% | – | – | – | |
| PDSBPDS Biotechnology Corporation | $68.7M | +5.1% | +2700.0% | 0% | – | – | – | |
| XLOXilio Therapeutics, Inc. | $56.7M | +1.4% | -12.2% | 0% | – | – | – | |
| ATNMActinium Pharmaceuticals, Inc. | $45M | +10.0% | +12800.0% | 101.1% | 4.0x | 0.8x | – | |
| ALGSAligos Therapeutics, Inc. | $25.4M | -9.8% | +528.0% | 99.2% | – | – | – | |
| CELUCelularity Inc. | $24.7M | +4.8% | +76.0% | 19.2% | – | – | – | |
| TPSTTempest Therapeutics, Inc. | $7.6M | +1.4% | +17800.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +302.0% | 9.6% | 4.0x | 0.8x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。